BioHarvest Sciences (NASDAQ:BHST - Get Free Report) is anticipated to announce its Q1 2025 earnings results after the market closes on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $7.80 million for the quarter.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last posted its earnings results on Monday, March 31st. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.05). The business had revenue of $7.17 million for the quarter, compared to the consensus estimate of $7.24 million. On average, analysts expect BioHarvest Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
BioHarvest Sciences Stock Performance
Shares of BHST traded down $0.03 during trading on Friday, reaching $6.44. 4,673 shares of the company traded hands, compared to its average volume of 18,029. The business's 50-day moving average is $5.98. The firm has a market cap of $105.78 million, a PE ratio of -5.16 and a beta of 0.80. BioHarvest Sciences has a twelve month low of $6.41 and a twelve month high of $7.38.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on BHST. Craig Hallum started coverage on BioHarvest Sciences in a research report on Monday, May 5th. They issued a "buy" rating and a $15.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $14.00 price target on shares of BioHarvest Sciences in a research note on Tuesday, April 8th.
Get Our Latest Research Report on BioHarvest Sciences
About BioHarvest Sciences
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
See Also
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
